Literature DB >> 9850455

Management of recipients of hepatic allografts harvested from donors with malignancy diagnosed shortly after transplantation.

O Detry1, P Honoré, N Jacquet, M Meurisse.   

Abstract

Transmission of undiagnosed malignancy with the graft is a dramatic complication of liver transplantation. Alternatives in the management of the recipients of livers, harvested from donors with malignancy diagnosed shortly after transplantation, are either early re-transplantation or close follow-up without re-operation. We reported 4 cases of liver recipients whose allografts were harvested from donors who were diagnosed with malignancy shortly after the liver transplantation. One recipient underwent re-transplantation, and the three other allografts were not removed. No recipient developed recurrence in the follow-up. While graft removal may be the only way to avoid tumor recurrence in recipients of liver graft harvested from donor with malignancy, close follow-up without re-operation may also be considered. The risk of tumor transferral may depend on the histopathological aggressiveness and metastatic potential of the donor tumor, and may be low for low-grade, local tumors. This risk should be evaluated by analyzing large series, using databases of Eurotransplant or United Network for Organ Sharing.

Entities:  

Mesh:

Year:  1998        PMID: 9850455

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

Review 1.  Donor-transmitted malignancy in a liver transplant recipient: a case report and review of literature.

Authors:  Brian Kim; Tinsay Woreta; Po-Hung Chen; Berkeley Limketkai; Andrew Singer; Nabil Dagher; Andrew Cameron; Ming-Tseh Lin; Ihab Kamel; Ahmet Gurakar
Journal:  Dig Dis Sci       Date:  2012-12-16       Impact factor: 3.199

2.  Cadaveric liver transplantation for non-acetaminophen fulminant hepatic failure: a 20-year experience.

Authors:  Olivier Detry; Arnaud De Roover; Carla Coimbra; Jean Delwaide; Marie-France Hans; Marie-Hélène Delbouille; Joseé Monard; Jean Joris; Pierre Damas; Jacques Belaïche; Michel Meurisse; Pierre Honoré
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.